This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Outcome of Board meeting dated May 18, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bharat Parenterals Limited's board approved FY26 audited results with unmodified (clean) audit opinions for both standalone and consolidated financials. Standalone revenue grew 14.6% to Rs. 2,340.1 crore from Rs. 2,041.3 crore, but net profit declined 39.4% to Rs. 160.2 crore from Rs. 264.5 crore. On a consolidated basis, the company reported a net loss of Rs. 273.1 crore (narrowing from Rs. 436.8 crore loss in FY25), with flat revenue of Rs. 3,454.3 crore versus Rs. 3,403.8 crore. EBITDA margin compressed significantly to 14.38% standalone (from 15.83%) and 4.58% consolidated (from 7.34%). The board recommended a final dividend of Rs. 1 per share (10%). Key auditor re-appointments include M/s. Chetan Gandhi & Associates as Cost Auditor and M/s. Dhruvik Parikh & Co. as Internal Auditor for FY27. The company acquired additional stake in subsidiary Varenyam Biolifesciences Private Limited during the year.
The standalone results show healthy revenue growth but declining profitability and margin compression, which may concern shareholders. The consolidated loss despite higher group revenue signals that subsidiary operations remain a drag on overall performance. The clean audit opinion and dividend are positives, but the negative PAT on consolidation is a key watch item.
| Q4 FY26 | Q4 FY25 | Change | |
|---|---|---|---|
| Revenue | ₹99.62 Cr | ₹104.0 Cr | −4.2% |
| Operating profit | −₹12.00 Cr | −₹10.50 Cr | loss widened |
| Profit after tax | −₹8.16 Cr | −₹9.44 Cr | loss narrowed |
| EBITDA margin | -0.5% | 2.1% | −2.7 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.